Phensuximide

Summary

Phensuximide (CHEMBL797) is an approved small molecule (ATC N03AD02); indicated across 1 condition including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AD02
• Indications: 1 condition
• Chemistry: 189.21 Da · C11H11NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL797
Name	Phensuximide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6839
ATC	N03AD02
Molecular formula	C11H11NO2
Molecular weight	189.21
InChIKey	WLWFNJKHKGIJNW-UHFFFAOYSA-N

SMILES: CN1C(=O)CC(C1=O)C2=CC=CC=C2

IUPAC name: 1-methyl-3-phenylpyrrolidine-2,5-dione

Also known as: Epimid, Fensuximida, Lifene, Milontin, Milonton, Mirontin, NSC-760079, Phensuximid, Phensuximide, PM-334, Racemic phensuximide, Succitimal

Patent coverage: 1,150 distinct patent families (4,734 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-lactamase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P00811	5.25	Potency	5623	nM	CHEMBL_ACT_4688749

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).